<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05790135</url>
  </required_header>
  <id_info>
    <org_study_id>4926</org_study_id>
    <nct_id>NCT05790135</nct_id>
  </id_info>
  <brief_title>Multiparametric Ultrasound Study in Diagnosing GvHD</brief_title>
  <acronym>ECO-STEM</acronym>
  <official_title>Evaluation of the Role of Multiparametric Ultrasound Study in Discriminating Among Intestinal Complications After Hematopoietic Stem Cell Transplantation. A Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluate the role of the use of bed-side multiparametric ultrasound study in the&#xD;
      diagnosis of gastrointestinal acute graft-versus host disease (aGvHD) in patients underwent&#xD;
      allogenic stem cell transplantation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The literature reports various experiences on the use of shear wave elastography (SWE) in the&#xD;
      study of the intestine, especially in patients with chronic inflammatory bowel diseases. But&#xD;
      few data are reported on the use of the method in patients with graft versus host disease.&#xD;
      Considering the simplicity of the method, we think it can be applied to an ultrasound study&#xD;
      of the intestine to try to understand the potential of SWE to further define the&#xD;
      characteristics of the intestinal segments involved.&#xD;
&#xD;
      Study population will include all patients submitted to allogenic stem cell transplantation&#xD;
      (SCT) who developed diarrhea &gt; 500 ml per day suggestive for aGvHD until 100 days from&#xD;
      transplant date. Patients submitted to autologous stem cell transplant who developed diarrhea&#xD;
      between transplant date and engraftment achievement will constitute control population as for&#xD;
      other infectious complications assessment. Within 24-48 hours from symptoms, onset full panel&#xD;
      of stool cultures will be performed together with Clostridium toxin assessment.&#xD;
      Multiparametric ultrasound study will be performed at the onset of the symptoms and then&#xD;
      weekly to monitoring intestinal changes accordingly to symptoms evolution during treatment.&#xD;
      In the case with high suspicion for aGvHD (stool culture negative, persistent or progressive&#xD;
      diarrhea, ultrasound imaging closely suggestive for aGvHD), as per common clinical practice,&#xD;
      colonoscopy will be required to evaluate internal macroscopy features of the bowel and to&#xD;
      obtain histological samples for conclusive diagnosis. In the meantime steroid therapy will be&#xD;
      started, as per common clinical practice. The only modification of this protocol to common&#xD;
      clinical practice is represented by the addition of a non-invasive bed-side method of&#xD;
      evaluation of the patients with diarrhea. None of the routinely performed diagnostic and&#xD;
      therapeutic process will be modified. All patients submitted to autologous stem cell&#xD;
      transplant who developed diarrhea between transplant date and engraftment achievement will&#xD;
      constitute control population. Also in this case full panel of stool culture and clostridium&#xD;
      toxin assessment will be performed at the onset of the symptoms. Multiparametric ultrasound&#xD;
      study will be made al symptoms onset and then weekly until symptom resolution.&#xD;
      Multiparametric ultrasound study will be performed by expert qualified staff as following:The&#xD;
      examinations will be performed at patient's bed, in supine position, with a MyLab™9 Platform&#xD;
      (by Esaote corporate, Italy) system. Fasting is required.&#xD;
&#xD;
      US for bowel requires both low-frequency convex probes (3.3-5 MHz) and high-frequency (5-17&#xD;
      MHz) linear assay probes to increase the spatial resolution of the intestinal wall and to&#xD;
      assess the wall diameter and wall layer.&#xD;
&#xD;
      Primary endpoint of the study is to evaluate the accuracy of bed-side multiparametric&#xD;
      ultrasound study in the diagnosis of gastrointestinal aGvHD in patients underwent to&#xD;
      allogenic transplant in terms of sensitivity, specificity, positive predictive value (PPV)&#xD;
      and negative predictive value (NPV). Secondary endpoints To assess potential associations&#xD;
      between bed-side multiparametric ultrasound measurements weekly performed and aGvHD diagnosis&#xD;
      in patients underwent to allogenic transplant. To assess whether bed-side multiparametric&#xD;
      ultrasound measurements at baseline differ in distinguishing complications different from&#xD;
      aGvHD (i.e., infectious, drug-related o neutropenic colitis) in patients underwent allogenic&#xD;
      transplant as compared to auto-transplant&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of bed-side multiparametric ultrasound study in gut-GvHD diagnosis will be measured and reported</measure>
    <time_frame>Onset of gastrointestinal symptoms within 100 days from transplant</time_frame>
    <description>Primary endpoint of the study is to evaluate the sensitivity of bed-side multiparametric ultrasound study in the diagnosis of gastrointestinal aGvHD in patients underwent to allogenic transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of bed-side multiparametric ultrasound study in gut-GvHD diagnosis will be measured and reported</measure>
    <time_frame>Onset of gastrointestinal symptoms within 100 days from transplant</time_frame>
    <description>Primary endpoint of the study is to evaluate the specificity of bed-side multiparametric ultrasound study in the diagnosis of gastrointestinal aGvHD in patients underwent to allogenic transplant</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Intestinal GVHD</condition>
  <arm_group>
    <arm_group_label>Multiparametric ultrasound evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiparametric ultrasound evaluation will be applied to all patients who will develop diarrhea above 500 ml per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>shear wave elastography</intervention_name>
    <description>Shear wave elastography and CEUS will be used to evaluate the reliability in diagnosing graft versus host disease of the gut after hematopoietic stem cell transplantation</description>
    <arm_group_label>Multiparametric ultrasound evaluation</arm_group_label>
    <other_name>contrast enhanced ultrasould (CEUS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years;&#xD;
&#xD;
          -  Submitted to first allogeneic stem cell transplant during the 12 months period of&#xD;
             enrollment of the study;&#xD;
&#xD;
          -  Diarrhea onset between day 0 and day +100 from transplant;&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous allogeneic stem cell transplantation;&#xD;
&#xD;
          -  Patients refusing to sign informed consent for the study;&#xD;
&#xD;
          -  Patients affected by severe cardiomyopathy and respiratory distress/insufficiency;&#xD;
&#xD;
          -  Patients unable to fully understand and accept study protocol for various problems&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabetta Metafuni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabetta Metafuni, MD</last_name>
    <phone>+39 3204475207</phone>
    <email>elisabetta.metafuni@policlinicogemelli.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabrizio Pizzolante, MD</last_name>
    <phone>+39 3381293824</phone>
    <email>fabrizio.pizzolante@policlinicogemelli.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Metafuni, MD</last_name>
      <phone>+39 3204475207</phone>
      <email>elisabetta.metafuni@policlinicogemelli.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 7, 2023</study_first_submitted>
  <study_first_submitted_qc>March 27, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 27, 2023</last_update_submitted>
  <last_update_submitted_qc>March 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCT</keyword>
  <keyword>GvHD</keyword>
  <keyword>gastrointestinal</keyword>
  <keyword>CEUS</keyword>
  <keyword>SWE</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 3, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT05790135/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

